"Inclusion in the FDA's TAP Program underscores the potential of Discure’s bioelectronic therapy, the Discure System, to reverse disc degeneration," said Yuval Mandelbaum, CEO of Discure ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback